نتایج جستجو برای: ambrisentan
تعداد نتایج: 197 فیلتر نتایج به سال:
Abstract Background Pulmonary arterial hypertension (PAH) is a progressive and fatal disease as such, it imperative that patients remain on therapy to delay progression maintain functional status. Previous research has demonstrated differences in overall survival the real-world by endothelin receptor antagonists (ERA) treatments with lower risk of death macitentan than ambrisentan bosentan. How...
Pulmonary arterial hypertension (PAH) is a progressive disease defined by a chronic elevation in pulmonary arterial pressure with extensive pulmonary vascular remodeling and perivascular inflammation characterized by an accumulation of macrophages, lymphocytes, dendritic cells, and mast cells. Although the exact etiology of the disease is unknown, clinical as well as preclinical data strongly i...
Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH). Bench to bedside scientific research has shown that endothelin-1 (ET-1) is overexpressed in several forms of pulmonary vascular disease and may play an important pathogenetic role in the development and progression of PAH. Oral endothelin receptor antagonists (ERAs) improved...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید